Workflow
港股异动丨签下创记录订单,晶泰控股飙升近23%
Ge Long Hui·2025-08-06 01:45

Core Viewpoint - Jingtai Holdings (2228.HK) experienced a significant stock price increase of nearly 23%, reaching HKD 8.1, marking a new high since February 25. This surge is attributed to the announcement of a substantial collaboration with DoveTree, involving a total order scale of approximately HKD 470 billion (USD 59.9 billion) for pipeline cooperation [1] Group 1 - On August 5, Jingtai Technology announced the completion of a collaboration agreement with DoveTree, which includes an initial payment of approximately HKD 4 billion (USD 510 million) [1] - The agreement covers multiple preclinical stage large and small molecule innovative drug assets, with a focus on new drug development targeting various specified targets by DoveTree [1] - DoveTree will hold exclusive global development and commercialization rights for the related drugs, while Jingtai Technology is entitled to receive further payments of approximately HKD 3.85 billion (USD 490 million) and potential milestone payments and sales shares amounting to about HKD 462 billion (USD 58.9 billion) [1] Group 2 - This collaboration sets a new record in the field of AI and robotics for new drug development order scale [1]